EXEL241220C39000
- 0.30
- 0.000.00%
Exelixis Newsroom
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $29 to $38
Exelixis Price Target Raised to $36.00/Share From $32.00 by Wells Fargo
Exelixis Is Maintained at Outperform by BMO Capital
Exelixis Analyst Ratings
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $29 to $38
Exelixis Analyst Ratings
TD Cowen Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $34
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $30 to $34
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $27 to $34
Exelixis Is Maintained at Market Outperform by JMP Securities
RBC Raises Price Target on Exelixis to $34 From $30, Keeps Outperform Rating
Goldman Sachs Remains a Sell on Exelixis (EXEL)
Exelixis Hold Rating: Navigating Legal Wins and Strategic Acquisitions Amid Uncertain Revenue Transition
Exelixis's Legal Triumph and Growth Prospects Bolster Buy Rating
Exelixis Analyst Ratings
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $31
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $33
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $33